Study of utidelone plus tirelizumab and bevacizumab for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing a combination of three drugs (utidelone, tirelizumab, and bevacizumab) for people with advanced or metastatic triple-negative breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if this combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 70 years old.
- You have triple-negative breast cancer that is advanced or has spread, and it has gotten worse after at least one round of standard chemotherapy that included taxanes or anthracyclines.
- Your cancer cannot be removed with surgery or has spread to other parts of the body.
- You have at least one tumor that can be measured on scans.
- You are in good enough health to get out of bed and take care of yourself (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and thyroid function are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
This trial tests a combination of three drugs (tislelizumab, bevacizumab, and capecitabine) in people with advanced solid tumors that have stopped responding to other treatments. It has specific groups for certain breast cancers and for people with brain metastases.
This trial tests a new drug called Trastuzumab Rezetecan, either alone or combined with Bevacizumab, for people with a specific type of advanced triple-negative breast cancer that has been treated with up to two prior therapies. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.